Down regulation of CD95 expression in high-risk AML patients as well its alterations in patients with acute promyeloblastic leukemia (APL) under all-trans retinoic acid therapy have been shown[34,35]. This evidence concerns the gene FAS and acute promyelocytic leukemia.